Gland Pharma Quarterly Results for Trading Insights
In Mar 2026, Gland Pharma (GLAND) reported revenue ₹1,854 Cr and net profit ₹367 Cr — revenue +26.2% YoY. View Gland Pharma 52-week for the annual high/low range and current price position.
GLAND Quarterly Results — Revenue, Profit & EPS Highlights
Gland Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit GLAND share price.
- Revenue of ₹1,854 Cr in Mar 2026 (-0.4% vs Jun 2026, +26.2% vs Mar 2025)
- Net Profit of ₹367 Cr in Mar 2026 (+15.8% vs Jun 2026, +96.3% vs Mar 2025)
- EBITDA of ₹625 Cr in Mar 2026 (+13.4% vs Jun 2026)
- Operating Margin of 29.0% in Mar 2026 (+2.0pp vs Jun 2026)
- Earnings Per Share of ₹22.26 in Mar 2026 (+15.8% vs Jun 2026)
Gland Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GLAND quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,854 | 1,862 | 1,571 | 1,469 | 1,563 | -0.4% | 26.2% |
| Net Profit (₹ Cr) | 367 | 317 | 184 | 187 | 216 | - | - |
| EBITDA (₹ Cr) | 625 | 551 | 398 | 392 | 425 | - | - |
| EPS (₹) | 22.26 | 19.23 | 11.15 | 11.32 | 13.08 | - | - |
| Operating Margin (%) | 29.0% | 27.0% | 21.0% | 24.0% | 24.0% | - | - |
GLAND Share Price Trend — 1-Year Movement Across Quarterly Results
Gland Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse GLAND FII DII holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GLAND vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gland Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores